Efficacy of hepatitis a vaccination and factors impacting on seroconversion in patients with inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 20, Issue 1, 2014, Pages 69-74

  Park, Sang Hyoung ^a   Yang, Suk Kyun ^a   Park, Soo Kyung ^a   Kim, Jong Wook ^a,b   Yang, Dong Hoon ^a   Jung, Kee Wook ^a   Kim, Kyung Jo ^a   Ye, Byong Duk ^a   Byeon, Jeong Sik ^a   Myung, Seung Jae ^a   Kim, Jin Ho ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

Hepatitis A virus; Immunosuppression; Inflammatory bowel disease; Vaccination

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; HEPATITIS A VACCINE; HEPATITIS VACCINE; INFLIXIMAB; MERCAPTOPURINE; PREDNISOLONE; TUMOR NECROSIS FACTOR INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; BLOOD EXAMINATION; CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY SCORE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS A; HEPATITIS C VACCINATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; SEROCONVERSION; TREATMENT RESPONSE; ULCERATIVE COLITIS; VACCINATION;

ADOLESCENT; ADULT; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HEPATITIS A; HEPATITIS A ANTIBODIES; HEPATITIS A VACCINES; HEPATITIS A VIRUS, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PROGNOSIS; PROSPECTIVE STUDIES; VACCINATION; YOUNG ADULT;

EID: 84893688307     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000437736.91712.a1     Document Type: Article

References (34)

1. Viget N, Vernier-Massouille G, Salmon-Ceron D, et al. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut. 2008;57:549-558.
2. Sands BE, Cuffari C, Katz J, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10: 677-692.
3. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009;3:47-91.
4. Wasan SK, Baker SE, Skolnik PR, et al. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol. 2010;105: 1231-1238.
5. Stevens R, Oliver M, Brogan M, et al. Defective generation of tetanusspecific antibody-producing B cells after in vivo immunization of Crohn's disease and ulcerative colitis patients. Gastroenterology. 1985;88:1860-1866.
6. Brogan MD, Shanahan F, Oliver M, et al. Defective memory B cell formation in patients with inflammatory bowel disease following tetanus toxoid booster immunization. J Clin Lab Immunol. 1987;24:69-74.
7. Mamula P, Markowitz JE, Piccoli DA, et al. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:851-856.
8. Lu Y, Jacobson DL, Ashworth LA, et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol. 2009;104:444-453.
9. Radzikowski A, Banaszkiewicz A, Lazowska-Przeorek I, et al. Immunogenecity of hepatitis A vaccine in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:1117-1124.
10. Gisbert JP, Villagrasa JR, Rodriguez-Nogueiras A, et al. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol. 2012; 107:1460-1466.
11. WHO. Evidence Based Recommendations for Use of Hepatitis A Vaccines in Immunization Services: Background Paper for SAGE Discussions, WHO Strategic Advisory Group of Experts on Immunization, 2011. Geneva, Switzerland: World Health Organization; 2011. Available at: http://www.who.int/immunization/sage/ previous-november2011/en/. Accessed March 4, 2013.
12. Hollinger FB, Ticehurst JR. Hepatitis A virus. In: Fields Virology. 3rd ed. Philadelphia, PA: Lippincott-Raven; 1996: 735-782.
13. Jung YK, Kim JH. Epidemiology and clinical features of acute hepatitis A: from the domestic perspective [in Korean]. Korean J Hepatol. 2009; 15:438-445.
14. Kim YJ, Lee HS. Increasing incidence of hepatitis A in Korean adults. Intervirology. 2010;53:10-14.
15. Park SH, Yang SK, Lim YS, et al. Clinical courses of chronic hepatitis B virus infection and inflammatory bowel disease in patients with both diseases. Inflamm Bowel Dis. 2012;18:2004-2010.
16. CDC. Recommended vaccinations indicated for adults based on medical and other indications. Available at: http://www.cdc.gov/vaccines/schedules/ hcp/imz/adult-conditions.html. Accessed September 10, 2013.
17. Moses J, Alkhouri N, Shannon A, et al. Response to hepatitis A vaccine in children with inflammatory bowel disease receiving infliximab. Inflamm Bowel Dis. 2011;17:E160.
18. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2-6; discussion 16-19.
19. Bovier PA. Epaxal: a virosomal vaccine to prevent hepatitis A infection. Expert Rev Vaccines. 2008;7:1141-1150.
20. Ambrosch F, Wiedermann G, Jonas S, et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine. 1997;15:1209-1213.
21. Bovier PA, Althaus B, Glueck R, et al. Tolerance and immunogenicity of the simultaneous administration of virosome hepatitis A and yellow fever vaccines. J Travel Med. 1999;6:228-233.
22. Bovier PA, Farinelli T, Loutan L. Interchangeability and tolerability of a virosomal and an aluminum-adsorbed hepatitis A vaccine. Vaccine. 2005;23:2424-2429.
23. Loutan L, Bovier P, Althaus B, et al. Inactivated virosome hepatitis A vaccine. Lancet. 1994;343:322-324.
24. Altunoz ME, Senates E, Yesil A, et al. Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls. Dig Dis Sci. 2012;57:1039-1044.
25. Wagner D, Wagenbreth I, Stachan-Kunstyr R, et al. Failure of vaccination against hepatitis B with Gen H-B-Vax-D in immunosuppressed heart transplant recipients. Clin Investig. 1992;70:585-587.
26. Worns MA, Teufel A, Kanzler S, et al. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases. Am J Gastroenterol. 2008;103:138-146.
27. Melmed GY, Agarwal N, Frenck RW, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:148-154.
28. Ramsay ME, Farrington CP, Miller E. Age-specific efficacy of pertussis vaccine during epidemic and non-epidemic periods. Epidemiol Infect. 1993;111:41-48.
29. Westerink MA, Schroeder HW Jr, Nahm MH. Immune responses to pneumococcal vaccines in children and adults: rationale for age-specific vaccination. Aging Dis. 2012;3:51-67.
30. Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940-987.
31. Hibi T, Naganuma M, Kitahora T, et al. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol. 2003;38:740-746.
32. Andoh A, Tsujikawa T, Ban H, et al. Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2008;23:1373-1377.
33. Lee HJ, Yang SK, Kim KJ, et al. The safety and efficacy of azathioprine and 6-mercaptopurine in the treatment of Korean patients with Crohn's disease. Intest Res. 2009;7:22-31.
34. Hepatitis B vaccines: WHO position paper. Wkly Epidemiol Rec. 2009;84: 405-420. Available at: http://www.who.int/wer/2009/wer8440/en/index. html. Accessed September 10, 2013.